CRISPR Therapeutics AG Stock Research

Market Summary

USD43.43+0.29

Market Closed

0.67%

CRSP Alerts

1 major insider sales recently.

CRSP Stock Price

CRSP RSI Chart

CRSP Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

-5.24

Price/Sales (Trailing)

2.8K

EV/EBITDA

-5.11

Price/Free Cashflow

-6.4

CRSP Price/Sales (Trailing)

CRSP Profitability

EBT Margin

-54298.83%

Return on Equity

-34.67%

Return on Assets

-28.99%

Free Cashflow Yield

-15.63%

CRSP Fundamentals

CRSP Revenue

Revenue (TTM)

1.2M

Revenue Y/Y

-99.95%

Revenue Q/Q

-93.62%

CRSP Earnings

Earnings (TTM)

-650.2M

Earnings Y/Y

21.72%

Earnings Q/Q

36.65%

Price Action

52 Week Range

38.9486.95

(Low)(High)

Last 7 days

-4.3%

Last 30 days

-13.8%

Last 90 days

-1.5%

Trailing 12 Months

-32.6%

CRSP Financial Health

Current Ratio

15.3

CRSP Investor Care

Shares Dilution (1Y)

1.98%

Diluted EPS (TTM)

-8.36

Peers (Alternatives to CRISPR Therapeutics AG)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	127.1B	26.3B	0.79%	2.78%	19.4	4.83	1.32%	11.18%
GILD	99.8B	27.3B	-4.19%	39.66%	21.72	3.66	-0.09%	-26.23%
MRNA	58.1B	19.3B	-4.61%	-16.03%	6.95	3.02	4.29%	-31.47%
BIIB	39.0B	10.2B	-0.92%	26.77%	12.8	3.83	-7.36%	95.80%
MID-CAP
NBIX	9.4B	1.5B	-5.59%	3.19%	60.62	6.29	31.34%	72.43%
DNLI	3.1B	108.5M	-21.66%	-32.82%	-9.55	28.71	122.90%	-12.19%
BBIO	2.2B	107.9M	21.83%	38.60%	-4.63	20.79	54.84%	17.36%
BEAM	2.2B	60.9M	-25.55%	-48.21%	-7.49	35.56	17.51%	22.00%
SMALL-CAP
RCUS	1.3B	112.0M	-7.70%	-49.25%	-4.81	11.47	-70.76%	-603.77%
REPL	1.1B	7.0M	-17.00%	22.02%	-7.14	159.78	131.81%	-45.39%
FATE	524.4M	96.3M	-14.58%	-86.07%	-1.86	5.45	72.44%	-32.79%
NVAX	519.7M	2.0B	-33.63%	-92.58%	-0.79	0.26	72.89%	62.27%
SGMO	276.9M	111.3M	-42.96%	-71.96%	-1.44	2.49	0.54%	-7.86%
VXRT	101.6M	107.0K	-17.23%	-85.52%	-0.94	949.93	-88.00%	-52.91%
IBIO	26.0M	-	40.00%	-84.44%	-0.32	3.21	0.51%	-185.61%

Financials for CRISPR Therapeutics AG

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-99.5%	1,198,000	229,639,250	458,080,500	686,521,750	914,963,000
Operating Expenses	-3.9%	674,359,000	701,409,000	648,600,000	603,265,000	541,435,000
S&GA Expenses	-2.4%	102,464,000	104,973,000	101,681,000	104,214,000	99,690,000
R&D Expenses	0.1%	461,645,000	461,185,000	428,063,000	387,172,000	340,567,000
EBITDA	3.5%	-626,328,000	-649,363,000	-601,681,000	337,710,000	-
EBITDA Margin	-18388.6%	-522	-2.83	-0.66	-	-
Earnings Before Taxes	3.5%	-650,500,000	-673,950,000	-626,574,000	316,510,000	379,531,000
EBT Margin	-18401.6%	-542	-2.93	-0.68	-	-
Net Income	4.5%	-650,175,000	-680,848,000	-633,452,000	311,607,000	377,661,000
Net Income Margin	-18205.0%	-542	-2.96	-0.69	-	-
Free Cahsflow	-4.8%	-532,929,000	-508,631,000	-515,774,000	414,365,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-4.7%	2,243	2,353	2,463	2,606	2,752
Current Assets	-4.1%	1,853	1,933	2,107	2,261	2,418
Cash Equivalents	-57.1%	212	494	497	684	923
Net PPE	-1.5%	164	166	165	157	138
Liabilities	-8.0%	368	399	373	361	352
Current Liabilities	-19.7%	121	151	120	114	120
Shareholder's Equity	-4.0%	1,875	1,954	2,091	2,245	2,399
Retained Earnings	-15.0%	-846	-735	-560	-375	-195
Additional Paid-In Capital	0.9%	2,735	2,709	2,670	2,635	2,598
Accumulated Depreciation	-45.3%	28.00	51.00	44.00	38.00	-
Shares Outstanding	0.3%	79.00	78.00	78.00	77.00	77.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-5.8%	-495	-468	-444	504	539
Share Based Compensation	-2.9%	98.00	101	103	106	102
Cashflow From Investing	-181.6%	-258	-91.84	-744	-982	-1,035
Cashflow From Financing	-9.0%	39.00	42.00	38.00	36.00	251

Risks for CRSP

What is the probability of a big loss on CRSP?

100%

Probability that CRISPR Therapeutics AG stock will be more than 20% underwater in next one year

88.1%

Probability that CRISPR Therapeutics AG stock will be more than 30% underwater in next one year.

80%

Probability that CRISPR Therapeutics AG stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRSP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CRISPR Therapeutics AG was unfortunately bought at previous high price.

Drawdowns

Returns for CRSP

Cumulative Returns on CRSP

-3.9%

5-Year Cumulative Returns

0.6%

3-Year Cumulative Returns

What are the long-term rolling returns for CRSP?

FIve years rolling returns for CRISPR Therapeutics AG.

Annualized Returns

Which funds bought or sold CRSP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	reduced	-17.56	-257,125	269,875	0.01%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	sold off	-100	-313,000	-	-%
2023-03-10	BAILLIE GIFFORD & CO	reduced	-8.73	-8,151,780	10,705,200	0.01%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-15.37	-2,952,000	3,283,000	0.02%
2023-03-02	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	new	-	25,813	25,813	-%
2023-03-02	OLIVER LAGORE VANVALIN INVESTMENT GROUP	reduced	-50.85	-93,740	41,260	0.02%
2023-02-28	Voya Investment Management LLC	added	1.23	-529,457	899,543	-%
2023-02-24	SRS Capital Advisors, Inc.	sold off	-100	-3,000	-	-%
2023-02-21	Boulder Wealth Advisors, LLC	new	-	8,000	8,000	0.01%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	reduced	-39.03	-90,554	55,446	-%

Latest Funds Activity

Are funds buying CRSP calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CRSP

No. of Funds

CRSP Alerts

1 major insider sales recently.

CRISPR Therapeutics AG News

Schedule 13G FIlings of CRISPR Therapeutics AG

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	capital international investors	7.1%	5,560,492	SC 13G
Feb 03, 2023	sumitomo mitsui trust holdings, inc.	5.11%	4,006,476	SC 13G/A
Feb 14, 2022	nikko asset management americas, inc.	5.64%	4,319,471	SC 13G/A
Feb 11, 2022	capital international investors	4.8%	3,706,004	SC 13G/A
Feb 09, 2022	ark investment management llc	11.88%	9,087,868	SC 13G/A
Feb 04, 2022	sumitomo mitsui trust holdings, inc.	5.64%	4,319,471	SC 13G/A
Sep 10, 2021	ark investment management llc	10.03%	7,644,350	SC 13G/A
Aug 10, 2021	capital international investors	5.6%	4,265,002	SC 13G/A
Feb 16, 2021	ark investment management llc	14.62%	10,412,976	SC 13G/A
Feb 16, 2021	capital international investors	10.7%	7,626,355	SC 13G/A

CRSP Fair Value

CRISPR Therapeutics AG fair value in different scenarios

The table shows the Fair Value estimates for CRISPR Therapeutics AG for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	7.65 -82.39%	8.24 -81.03%	10.03 -76.91%	12.82 -70.48%	17.78 -59.06%
Current Inflation	7.53 -82.66%	8.04 -81.49%	9.62 -77.85%	12.04 -72.28%	16.32 -62.42%
Very High Inflation	7.37 -83.03%	7.80 -82.04%	9.12 -79.00%	11.10 -74.44%	14.60 -66.38%

Historical CRISPR Therapeutics AG Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of CRISPR Therapeutics AG

View All Filings

Date Filed	Form Type	Document
Mar 14, 2023	3	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	8-K	Current Report
Mar 01, 2023	4	Insider Trading
Feb 22, 2023	4	Insider Trading
Feb 22, 2023	4	Insider Trading
Feb 22, 2023	4	Insider Trading

Latest Insider Trading transactions for CRSP

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-13	Kulkarni Samarth	sold (taxes)	-408,170	43.22	-9,444	chief executive officer
2023-03-13	KASINGER JAMES R.	sold (taxes)	-99,622	43.22	-2,305	general counsel and secretary
2023-03-11	KASINGER JAMES R.	acquired	-	-	2,250	general counsel and secretary
2023-03-11	Kulkarni Samarth	acquired	-	-	9,000	chief executive officer
2023-03-10	KASINGER JAMES R.	acquired	-	-	2,833	general counsel and secretary
2023-03-10	Kulkarni Samarth	acquired	-	-	11,833	chief executive officer
2023-02-27	Kulkarni Samarth	acquired	478,000	19.12	25,000	chief executive officer
2023-02-27	Kulkarni Samarth	sold	-1,206,240	48.2497	-25,000	chief executive officer
2023-02-21	Smith Brendan	sold (taxes)	-67,177	48.26	-1,392	chief financial officer
2023-02-21	Kulkarni Samarth	sold (taxes)	-307,561	48.26	-6,373	chief executive officer

About CRISPR Therapeutics AG

Samarth Kulkarni

www.crisprtx.com

470

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRSP Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 1,198	$ 914,963	$ 719
Operating expenses:
Research and development	461,645	340,567	221,382
General and administrative	102,464	99,690	85,747
Collaboration expense, net	110,250	101,178	48,025
Total operating expenses	674,359	541,435	355,154
(Loss) income from operations	(673,161)	373,528	(354,435)
Other income
Other income, net	22,661	6,003	6,379
Total other income, net	22,661	6,003	6,379
Net income (loss) before income taxes	(650,500)	379,531	(348,056)
Benefit (provision) for income taxes	325	(1,870)	(809)
Net (loss) income	(650,175)	377,661	(348,865)
Foreign currency translation adjustment	(80)	(11)	40
Unrealized loss on marketable securities	(10,500)	(4,973)	(130)
Comprehensive (loss) income	$ (660,755)	$ 372,677	$ (348,955)
Net (loss) income per common share - basic	$ (8.36)	$ 4.97	$ (5.29)
Basic weighted-average common shares outstanding	77,746,575	75,948,686	65,949,672
Net (loss) income per common share - diluted	$ (8.36)	$ 4.70	$ (5.29)
Diluted weighted-average common shares outstanding	77,746,575	80,393,496	65,949,672
Collaboration Revenue [Member]
Revenue:
Total revenue	$ 436	$ 913,081	$ 543
Grant Revenue [Member]
Revenue:
Total revenue	$ 762	$ 1,882	$ 176

CRSP Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 211,885	$ 923,031
Marketable securities	1,603,433	1,456,098
Accounts receivable	0	305
Prepaid expenses and other current assets	37,708	38,079
Total current assets	1,853,026	2,417,513
Property and equipment, net	163,634	137,575
Marketable securities, non-current	53,130	0
Intangible assets, net	71	125
Restricted cash	11,635	16,913
Operating lease assets	156,921	174,460
Other non-current assets	4,640	5,291
Total assets	2,243,057	2,751,877
Current liabilities:
Accounts payable	27,428	14,816
Accrued expenses	77,682	91,003
Deferred revenue, current	0	1,011
Accrued tax liabilities	135	724
Operating lease liabilities	15,842	12,158
Other current liabilities	20	171
Total current liabilities	121,107	119,883
Deferred revenue, non-current	12,323	12,323
Operating lease liabilities, net of current portion	228,179	212,872
Other non-current liabilities	5,969	7,339
Total liabilities	367,578	352,417
Commitments and contingencies (Note 9)
Shareholders’ equity:
Common shares, CHF 0.03 par value, 150,347,467 and 145,364,335 shares authorized at December 31, 2022 and 2021, respectively, 78,692,766 and 77,170,382 shares issued at December 31, 2022 and 2021, respectively, 78,512,450 and 76,990,066 shares outstanding at December 31, 2022 and 2021, respectively.	2,441	2,391
Treasury shares, at cost, 180,316 shares at December 31, 2022 and 2021, respectively	(63)	(63)
Additional paid-in capital	2,734,838	2,598,114
Accumulated deficit	(846,090)	(195,915)
Accumulated other comprehensive loss	(15,647)	(5,067)
Total shareholders’ equity	1,875,479	2,399,460
Total liabilities and shareholders’ equity	$ 2,243,057	$ 2,751,877